Valeant Pharma (VRX) Posts Mixed Q4
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance
February 28, 2018 7:00 AM ESTLAVAL, Quebec, Feb. 28, 2018 /PRNewswire/ --
Fourth-Quarter 2017 Financial Results Revenues of $2.163 Billion GAAP Net Income of $513 Million GAAP Cash Flow from Operations of $578 Million Adjusted EBITDA (non-GAAP)1 of $875 Million Full-Year 2017 Financial Results Revenues of $8.724 Billion GAAP Net Income of $2.404 Billion GAAP Cash Flow from Operations of $2.290 Billion Adjusted EBITDA (non-GAAP) of $3.638 BillionValeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX:... More
